MX2022006655A - Uso de nucleosomas libres de celulas como biomarcadores. - Google Patents

Uso de nucleosomas libres de celulas como biomarcadores.

Info

Publication number
MX2022006655A
MX2022006655A MX2022006655A MX2022006655A MX2022006655A MX 2022006655 A MX2022006655 A MX 2022006655A MX 2022006655 A MX2022006655 A MX 2022006655A MX 2022006655 A MX2022006655 A MX 2022006655A MX 2022006655 A MX2022006655 A MX 2022006655A
Authority
MX
Mexico
Prior art keywords
biomarkers
cell free
free nucleosomes
nucleosomes
vascular
Prior art date
Application number
MX2022006655A
Other languages
English (en)
Inventor
Mark Edward Eccleston
Jacob Vincent Micallef
Heather Wilson-Robles
Marielle Chantal Andree Herzog
Jason Bradley Terrell
Original Assignee
Belgian Volition Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belgian Volition Srl filed Critical Belgian Volition Srl
Publication of MX2022006655A publication Critical patent/MX2022006655A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a nucleosomas libres de células como biomarcadores en muestras de plasma para detectar cánceres vasculares o hematológicos.
MX2022006655A 2019-12-02 2020-12-02 Uso de nucleosomas libres de celulas como biomarcadores. MX2022006655A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962942596P 2019-12-02 2019-12-02
US202063088408P 2020-10-06 2020-10-06
PCT/EP2020/084328 WO2021110776A1 (en) 2019-12-02 2020-12-02 Use of cell free nucleosomes as biomarkers

Publications (1)

Publication Number Publication Date
MX2022006655A true MX2022006655A (es) 2022-09-07

Family

ID=73698838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006655A MX2022006655A (es) 2019-12-02 2020-12-02 Uso de nucleosomas libres de celulas como biomarcadores.

Country Status (12)

Country Link
US (1) US20230003735A1 (es)
EP (1) EP4070111A1 (es)
JP (1) JP2023503379A (es)
KR (1) KR20220110794A (es)
CN (1) CN114829939A (es)
AU (1) AU2020395504A1 (es)
BR (1) BR112022010774A2 (es)
CA (1) CA3163181A1 (es)
IL (1) IL293342A (es)
MX (1) MX2022006655A (es)
TW (1) TW202134654A (es)
WO (1) WO2021110776A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023073179A1 (en) 2021-10-29 2023-05-04 Belgian Volition Srl Homogeneous immunoassay method
GB202117799D0 (en) 2021-12-09 2022-01-26 Belgian Volition Srl Method for the detection of blood cancer
WO2023170298A1 (en) 2022-03-11 2023-09-14 Belgian Volition Srl Differential diagnosis method
WO2024042210A1 (en) 2022-08-25 2024-02-29 Belgian Volition Srl Method for measuring cell free chromatin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319376D0 (en) 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
ATE534908T1 (de) * 2009-08-03 2011-12-15 Universitaetsklinikum Freiburg Verfahren und verbindungen zur diagnose und behandlung von krebs
GB201115099D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
GB201115098D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
SG11201402982TA (en) 2011-12-07 2014-07-30 Singapore Volition Pte Ltd Method for detecting nucleosome adducts
ES2930180T3 (es) * 2012-03-02 2022-12-07 Sequenom Inc Métodos para enriquecer ácido nucleico canceroso a partir de una muestra biológica
US9388213B2 (en) * 2012-09-10 2016-07-12 The Rockefeller University Polycomb repressive complex 2 (PRC2) inhibitors and uses thereof
JP6721599B2 (ja) 2014-10-29 2020-07-15 ベルジアン ボリション エスピーアールエル 循環する腫瘍ｄｎａの濃縮方法
GB201511542D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell free nucleosomes as biomarkers
GB201511512D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell-free nucleosomes as biomarkers
GB201518674D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for detecting nuleosomes containing histone modifications and variants
CN111918971A (zh) * 2018-03-01 2020-11-10 埃皮塞弗公司 利用化学确定的重组核小体定量核小体修饰

Also Published As

Publication number Publication date
AU2020395504A1 (en) 2022-06-23
CA3163181A1 (en) 2021-06-10
EP4070111A1 (en) 2022-10-12
JP2023503379A (ja) 2023-01-27
BR112022010774A2 (pt) 2022-08-23
WO2021110776A1 (en) 2021-06-10
TW202134654A (zh) 2021-09-16
KR20220110794A (ko) 2022-08-09
IL293342A (en) 2022-07-01
CN114829939A (zh) 2022-07-29
US20230003735A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
MX2022006655A (es) Uso de nucleosomas libres de celulas como biomarcadores.
MX2017016647A (es) Anticuerpos y fragmentos anti-vista.
MY186712A (en) Methods and compositions for inhibiting the interaction of menin with mll proteinss
WO2014160499A3 (en) Methods and compositions for detecting pancreatic cancer
GB2511221A (en) Methods and compositions for classification of samples
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
WO2018187496A8 (en) PLASMA PROTEIN PROFILING FOR THE EARLY PROGNOSIS OF LUNG CANCER
EP3862439A3 (en) Liver cancer detection kit or device, and detection method
MX2015014734A (es) Composiciones y metodos para alterar la señalizacion del segundo mensajero.
MX2017009768A (es) Ligadores lábiles para detección de biomarcadores.
EP3654036A3 (en) Stomach cancer biomarker and detection method
MX2017009998A (es) Biomarcadores para cancer pancreatico.
WO2013107459A3 (en) Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
MA40390A (fr) Procédés d'analyse impliquant des nanoparticules dissociables
MX2017014735A (es) Metilacion de promotor pd-l1 en cancer.
EP3201812A4 (en) Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample
EP3686290A3 (en) Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
EP3176268A4 (en) Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof
MX2019006005A (es) Metodos para la deteccion de cancer.
EP4345159A3 (en) Methods for trapping and barcoding discrete biological units in hydrogel
MX2018013223A (es) Reacción de cadena de polimerasas para amplificación de discordancias optimizada multiplicada (moma)-en tiempo real para la valoración de cáncer.
MX2016011748A (es) Anticuerpos humanizados con estabilidad incrementada.
MX2017011198A (es) Biomarcadores para preeclampsia.
MX365713B (es) Enriquecimiento de células tumorales circulantes por desgaste de glóbulos blancos.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.